Topamax Contre Indication

Note 4.8 étoiles, basé sur 201 commentaires.

This drug may make you dizzy or ciberperiodismo.72ppp.org or impair your Topamax Contre indication.

Alcohol or marijuana cannabis can worsen these effects. Do not drive, use machinery, or do anything that needs alertness until you can do it safely.

Talk to your nh-apartments.000webhostapp.com if you are using marijuana cannabis. This medication may make you sweat less, making you more likely to get heat stroke.

Side Effects

Avoid doing things that may cause you to overheat, such as hard work or exercise in hot weather, or using hot tubs. When the Topamax Contre indication is hot, drink a lot of fluids and dress lightly, Topamax Contre Indication. If you overheat, quickly look for a place to cool down and rest. Before having surgery, Topamax Contre Indication, tell your doctor or dentist about all the products you use including prescription drugsnonprescription drugs, and herbal products.

Children may be more sensitive to the side effects of this drug, especially weakened bones, slowed growth rate, and decreased sweating, Topamax Contre Indication. Consult your doctor or pharmacist for more details. Older adults may be more sensitive to the side effects of this drug, especially dizziness.

Moderate Concurrent administration of topiramate with ritonavir may result in decreased concentrations of ritonavir. Ritonavir is metabolized by this enzyme. Moderate Delavirdine is a potent inhibitor of cytochrome P 2C9 and might decrease topiramate metabolism leading to increased topiramate serum concentrations and a risk of adverse reactions.

Moderate Use dichlorphenamide and topiramate, another carbonic anhydrase inhibitor, together with caution as both drugs can cause metabolic acidosis. Concurrent use may increase the severity of metabolic acidosis.

Measure sodium bicarbonate concentrations at baseline and periodically during dichlorphenamide treatment. If metabolic acidosis occurs or persists, consider reducing the dose or discontinuing dichlorphenamide therapy. Although the clinical relevance has not been determined, the Topamax Contre indication should be aware that serum digoxin concentrations may be affected when digoxin and topiramate are used concomitantly, Topamax Contre Indication. Moderate Coadministrator topiramate with diltiazem with caution.

Monitor for loss of diltiazem efficacy and or increased adverse events coming from the topiramate component of phentermine;topiramate, Topamax Contre Indication. Moderate Close clinical monitoring is advised when administering topiramate with rilpivirine due to the potential for rilpivirine treatment failure.

Although this interaction has not been studied, predictions can be made based on metabolic pathways. Topiramate is an inducer of the hepatic isoenzyme CYP3A4; rilpivirine is metabolized by this isoenzyme.

Coadministration may result in decreased rilpivirine serum concentrations and impaired virologic response. Minor Concurrent administration of doravirine and topiramate may result in decreased doravirine exposure, resulting in potential loss of virologic control.

Doravirine; Lamivudine; Tenofovir disoproxil fumarate: Inducers of CYP3A4 may decrease the concentration of doxorubicin and compromise the efficacy of chemotherapy. Avoid coadministration of topiramate and doxorubicin if possible.

If not possible, Topamax Contre indication doxorubicin closely for efficacy. Moderate Use caution if coadministration of dronabinol with topiramate is necessary, and monitor for a decrease in the efficacy of dronabinol. Concomitant use may result in decreased plasma concentrations of dronabinol.

Dronedarone is metabolized by CYP3A.

What do I need to tell my doctor BEFORE I take Topiramate Tablets?

Coadministration of CYP3A4 inducers, Topamax Contre Indication, such as topiramate, with dronedarone may result in reduced plasma concentration and subsequent reduced effectiveness of dronedarone therapy.

Drospirenone; Ethinyl Estradiol; Levomefolate: Moderate Caution is advised when administering elbasvir with topiramate.

Use of these Topamax Contre indications together may decrease the plasma concentrations of elbasvir and could result in decreased virologic response. Moderate Caution is advised when administering elbasvir; grazoprevir with topiramate.

Use of these drugs together may decrease the plasma concentrations of grazoprevir and could result in decreased virologic response.

Uses of Topiramate Tablets:

For patients requiring use of such drugs, an alternative to linagliptin is strongly recommended. Emtricitabine; Rilpivirine; Tenofovir alafenamide: Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Major Topiramate can increase the clearance of estrogens and compromise the efficacy of estrogens used as hormone replacement therapies or contraceptives.

Patients taking oral contraceptives, non-oral combination contraceptives, or progestions for contraception or patients taking estrogens or progestins for hormone replacement therapy should report changes in their bleeding patterns to their prescribers. Dosages of the products may need adjustment; the manufacturer of topiramate recommends that an oral contraceptive containing 50 mcg of ethinyl estradiol be used. Major Ethanol consumption is contraindicated within 6 hours prior to and 6 hours after administration of topiramate extended-release capsules.

The pattern of topiramate release from the extended-release capsule is significantly altered in the presence of alcohol. This may result in significantly increased plasma levels of topiramate soon after dosing followed by subtherapeutic levels later in the day. Because of the possibility of additive CNS depressant effects, other dosage formulations of topiramate should be used with extreme caution if used in combination with alcohol. Ethinyl Estradiol; Ethynodiol Diacetate: Ethinyl Estradiol; Levonorgestrel; Ferrous bisglycinate: Ethinyl Estradiol; Norethindrone Acetate: Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: Ethinyl Estradiol; Norethindrone; Ferrous fumarate: Moderate Monitor for clinical Topamax Contre indication of etoposide if used concomitantly with topiramate.

Coadministration of etoposide Topamax Contre indication a strong CYP3A4 inducer phenytoin resulted in increased etoposide clearance and reduced Topamax Contre indication, as did coadministration with a weak inducer of CYP3A4 and P-glycoprotein P-gp valproic acid. Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant ezogabine, may increase the risk of bleeding.

Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant felbamate may increase the risk of bleeding, Topamax Contre Indication. Major The concomitant use of flibanserin with CYP3A4 inducers significantly decreases flibanserin exposure compared to the use of flibanserin alone, Topamax Contre Indication.

Therefore, concurrent use of flibanserin and CYP3A4 inducers, Topamax Contre Indication, such as topiramate is not recommended. Moderate Concurrent use of topiramate and drugs that affect platelet function such as selective serotonin reuptake inhibitors SSRIs like fluoxetine may increase the risk of bleeding.

Moderate Concurrent use of topiramate and drugs that affect platelet function such as selective serotonin reuptake inhibitors SSRIs like fluvoxamine may increase the risk of bleeding.

Moderate Topiramate may influence the pharmacokinetic profile of cannabinoids in Marijuana and may also influence the pharmacodynamic profile, Topamax Contre Indication. This may result in an altered adverse event profile of one or both drugs.

Topiramate is an inducer of CYP3A4, Topamax Contre Indication, an isoenzyme partially responsible for the metabolism of marijuana’s most psychoactive compound, deltatetrahydrocannabinol THC. More study is needed to determine the magnitude and cliniical significance of any pharmacokinetic or pharmacodynamic interactions.

Additive drowsiness and CNS depression is possible, Topamax Contre Indication. Monitor for changes in moods or behaviors, or for other CNS effects. Moderate Monitor for clinical response of gefitinib if used concomitantly with topiramate. Gefitinib is metabolized significantly by CYP3A4 and topiramate is a weak CYP3A4 inducer; coadministration may increase gefitinib metabolism and decrease gefitinib concentrations.

This also applies to combination products containing topiramate, such as phentermine; topiramate. Minor Coadministration of glyburide with topiramate may decrease systemic exposure to glyburide. A pharmacokinetic drug interaction study evaluated the combination of topiramate and glyburide.

Reductions in AUC and Cmax were noted for glyburide and the active metabolites. Topiramate may increase phenytoin concentrations through its inhibitory effects on CYP2C These patients were generally receiving dosage regimens of phenytoin twice-daily, Topamax Contre Indication.

A similar reaction would be expected with fosphenytoin or ethotoin. Concurrent use of topiramate and drugs that cause thrombocytopenia, such as the hydantoins, may also increase the risk of bleeding; monitor patients appropriately.

Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Moderate Caution is warranted with the coadministration of hydroxychloroquine and antiepileptic drugs, such as topiramate. Hydroxychloroquine can lower the seizure threshold; therefore, the activity of antiepileptic drugs may be impaired with concomitant use. Moderate Imatinib is a potent inhibitors of cytochrome P 2C9 and might decrease topiramate metabolism leading to increased topiramate serum concentrations and a risk of adverse reactions.

Moderate Caution and close monitoring are warranted when isavuconazonium is administered with topiramate as there is a potential for decreased concentrations of isavuconazonium.

Decreased isavuconazonium concentrations may lead to a reduction of antifungal efficacy and the potential for treatment failure. Isavuconazole, the active moiety of isavuconazonium, is a sensitive substrate of this enzyme. Major Avoid coadministration of ivabradine and topiramate.

Coadministration may decrease the plasma concentrations of ivabradine resulting in the potential for treatment failure. Kava Kava, Piper methysticum: While the interactions can be pharmacodynamic in nature, kava kava has been reported to inhibit many CYP isozymes i.

Persons taking an anticonvulsant should discuss the use of herbal supplements with their health care professional prior to consuming them. Moderate Use lacosamide with caution in patients taking concomitant medications that affect cardiac conduction including those that prolong PR interval, such as sodium channel blocking anticonvulsants e, Topamax Contre Indication.

Topiramate Tablets

If use together is necessary, obtain an ECG prior to lacosamide initiation and after treatment has been titrated to steady-state. In addition, monitor patients receiving lacosamide via the intravenous route closely. Moderate Use caution when coadministering lamotrigine and topiramate.

Concurrent use of topiramate and drugs that cause thrombocytopenia, such as lamotrigine, may increase the risk of bleeding. Concurrent use may also result in significant CNS depression. Plasma concentrations of lamotrigine do not appear to be affected by the combined use of the Topamax Contre indications. Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant levetiracetam, may Topamax Contre indication the risk of bleeding.

Lithium levels should be monitored; monitor patients for adequate control of symptoms when phentermine; topiramate is added to Topamax Contre indication therapy. Moderate Monitor for additive sedation during coadministration of lofexidine and anticonvulsants. Lofexidine can potentiate the effects of CNS depressants.

Patients should be advised to avoid driving or performing any other tasks requiring mental alertness until the effects of the combination are known. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with topiramate. Loperamide is metabolized by the hepatic enzyme CYP3A4; topiramate is a mild inducer of this enzyme.

Low Molecular Weight Heparins: Moderate Because lurasidone is primarily metabolized by CYP3A4, decreased plasma concentrations of lurasidone may theoretically occur when the drug is co-administered with inducers of CYP3A4 such as topiramate. Moderate Maprotiline, when used concomitantly with anticonvulsants, can increase CNS depression and may also lower the seizure threshold, leading to pharmacodynamic interactions.

Monitor patients on anticonvulsants carefully when maprotiline is used concurrently. Because of the lowering of seizure threshold, an alternative antidepressant may be a more optimal choice for patients taking drugs for epilepsy. Minor Use caution if coadministration of maraviroc with topiramate is necessary, Topamax Contre Indication, due to a possible decrease in maraviroc exposure. Monitor for a decrease in maraviroc efficacy with concomitant use. Moderate Coadministration of mefloquine and anticonvulsants may result in lower than expected anticonvulsant concentrations and loss of seizure control.

Monitoring of the anticonvulsant serum concentration is recommended. Dosage adjustments may be required during and Topamax Contre indication therapy with mefloquine. Methenamine; Sodium Acid Phosphate: Moderate Consistent with the pharmacology of molindone, additive effects may occur with other CNS active drugs such as anticonvulsants, Topamax Contre Indication.

In addition, seizures have been reported during the use of molindone, which is of particular significance in patients with a seizure disorder receiving anticonvulsants.

Adequate dosages of anticonvulsants should be continued when molindone is added; patients should be monitored for clinical evidence of loss of seizure control or the need for dosage adjustments of either molindone or the anticonvulsant. Major Avoid coadministration of nisoldipine with topiramate due to decreased plasma concentrations of nisoldipine, Topamax Contre Indication. Alternative antihypertensive therapy should be considered.

Coadministration with a strong CYP3A4 inducer lowered nisoldipine plasma concentrations to undetectable levels. Moderate Concurrent use of topiramate and drugs that affect platelet function such as selective serotonin reuptake inhibitors SSRIs like paroxetine may increase the risk of bleeding. Moderate Coadministration of pazopanib and topiramate may cause a decrease in systemic concentrations of pazopanib, Topamax Contre Indication. Use caution when administering these drugs concomitantly.

Pazopanib is a substrate for CYP3A4. Topiramate in a weak CYP3A4 inducer, Topamax Contre Indication. Major A Topamax Contre indication in seizure threshold has been reported following concomitant administration of pemoline with anticonvulsant agents. Dosage adjustments of anticonvulsants may be necessary during simultaneous use of these drugs. Topiramate is an inducer of CYP3A4, while perampanel is a substrate of this enzyme. Patients taking topiramate who begin treatment with perampanel should be closely monitored for adverse effects and receive a higher initial dose of perampanel.

Addition or withdrawal of enzyme-inducing antiepileptic drugs may require a perampanel dose adjustment. Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant pregabalin, may increase the risk of bleeding. Minor Probenecid may increase the renal clearance of topiramate resulting in lower topiramate concentrations. Although not evaluated in humans, animal studies using probenecid along with topiramate showed a significant increase in renal clearance of topiramate.

PDR Search

This suggests that topiramate may undergo renal tubular reabsorption. Probenecid may block renal tubular reabsorption of topiramate, thus increasing the renal Topamax Contre indication of the drug. Moderate Concurrent use of topiramate and anticoagulants may increase the risk of bleeding. However, coadministration of rivaroxaban and topiramate may result in decreased rivaroxaban exposure and may decrease the efficacy of rivaroxaban. If these drugs are administered concurrently, Topamax Contre Indication, monitor the patient for signs of bleeding or lack of efficacy of rivaroxaban.

Coadministration of a CYP3A4 inducer, like topiramate, may decrease systemic concentrations of romidepsin. Use caution when concomitant administration of these agents is necessary. Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant rufinamide, may increase the risk of bleeding.

Moderate Concurrent use of topiramate and drugs that affect platelet function such as selective serotonin reuptake inhibitors SSRIs like topiramate may increase the risk of bleeding.

Major Avoid concurrent use of simeprevir and topiramate. Induction of CYP3A4 by topiramate may significantly reduce the plasma concentrations of simeprevir, resulting in treatment failure. Major Use caution when administering velpatasvir with topiramate.

Taking these Topamax Contre indications together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Moderate Because the dose of the sufentanil sublingual tablets cannot be titrated, consider an alternate opiate if topiramate must be administered. Monitor for reduced efficacy of sufentanil injection and signs of opioid withdrawal if coadministration with topiramate is necessary; consider increasing the dose of sufentanil injection as needed.

If topiramate is discontinued, consider a dose reduction of sufentanil injection and frequently monitor for signs or respiratory depression and sedation. Concomitant use with CYP3A4 inducers can Topamax Contre indication sufentanil Topamax Contre indications this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.

Moderate Caution is warranted when topiramate is administered with telithromycin as there is a potential for decreased telithromycin concentrations and loss of Topamax Contre indication.

Telithromycin is a substrate of CYP3A4. Moderate Caution is advised when administering terbinafine with topiramate. Although this interaction has not been studied by the manufacturer, and published literature suggests the potential for interactions to be low, taking these drugs together may alter the systemic exposure of terbinafine.

Predictions about the interaction can be made based on the metabolic pathways of both drugs. Monitor patients for adverse reactions and breakthrough fungal infections if these drugs are coadministered. Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant tiagabine, may increase the risk of bleeding. Topiramate is an inducer of CYP3A4. Coadministration may result in reduced plasma concentration and subsequent reduced effectiveness of tolvaptan therapy and should be avoided.

If coadministration is unavoidable, an increase in the tolvaptan dose may be necessary and patients should be monitored for decreased effectiveness of tolvaptan. Moderate Trazodone can lower the seizure threshold of anticonvulsants, although the overall risk is low at therapeutic doses. Patients may require increased concentrations of anticonvulsants to achieve equivalent effects if trazodone is added.

Monitor for decreased clinical Topamax Contre indications of tretinoin, Topamax Contre Indication, ATRA while receiving concomitant therapy. Moderate Oligohidrosis and hyperthermia have been reported in post-marketing experience with topiramate. Use caution when topiramate is prescribed with agents known to predispose patients to similar heat-related disorders such as trospium.

Concomitant use may Topamax Contre indication the plasma concentration and effectiveness of ulipristal. Valproic Acid, Divalproex Sodium: Major Concomitant Topamax Contre indication of topiramate and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone.

In addition, Topamax Contre Indication, concomitant administration of topiramate and valproic acid has been associated with hypothermia with or without hyperammonemia in patients who have tolerated either drug alone.

Assessment of blood ammonia levels may be advisable in patients presenting with symptoms of hypothermia. Concurrent use of topiramate and drugs that cause thrombocytopenia, such as valproic acid, may also increase the risk of bleeding; monitor patients appropriately. In several case reports, children with localized epilepsy have presented with somnolence, Topamax Contre Indication, seizure exacerbation, behavioral alteration, decline in speech and cognitive abilities, and ataxia while being treated with a combination of valproate and topiramate.

Previously, the children tolerated valproic acid with other antiepileptic drugs. Children presented with elevated serum Topamax Contre indication, normal or elevated LFTs, and generalized slowing of EEG background activity during encephalopathy, which promptly reverted to Topamax Contre indication along with clinical improvement following withdrawal of valproate.

The possible mechanism is topiramate-induced aggravation of all the known complications of valproic acid monotherapy; it is not due to a pharmacokinetic interaction. This condition is reversible with cessation of either valproic acid or topiramate.

blog.rizolit-karelia.com


NEuACKJ

Комментарии закрыты.